New hope for hard-to-treat lymphoma: experimental combo targets relapsed patients
NCT ID NCT07355283
First seen Jan 23, 2026 · Last updated Apr 30, 2026 · Updated 12 times
Summary
This study tests whether adding the experimental drug IMM0306 to standard lenalidomide helps people with relapsed or refractory follicular lymphoma achieve complete remission and live longer without the cancer worsening. About 198 adults who have already tried at least two prior treatments will be randomly assigned to receive either IMM0306 plus lenalidomide or a placebo plus lenalidomide. The trial is double-blind, meaning neither patients nor doctors know who gets the experimental drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.